Loading
Life sciences · Journal article
Acs Materials Letters · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract High-entropy nanomaterials (HEMs) are advancing catalytic cancer therapy. The prevailing view treats entropy as a performance-enhancing design parameter, assuming it improves activity by broadening active-site chemistries. This review reframes that view as an oversimplification, positioning entropy as a contingent design variable realized only when it resolves durability or robustness limitations beyond lower-entropy materials, not as a general-purpose performance multiplier. Tumor microenvironment constraints—acidity, hypoxia, redox imbalance, and glutathione abundance—limit conventional nanoagents' durability. Under such constraints, entropy-stabilized atomic heterogeneity can generate distributed active sites, electronic delocalization, and resistance to thiol-induced deactivation, enabling functional coexistence beyond compositional additivity. Multifunctionality introduces trade-offs: reduced selectivity, uncontrolled reactive oxygen species generation, and active-site interference. HEMs are justified only when entropy is essential for catalytic persistence under competing biological constraints, not when it merely correlates with improved activity in a single assay. Rigorous benchmarks—phase stability, durability, and lower-entropy comparators—should guide design toward safe, translational deployment.